Crizotinib-induced immunogenic cell death in non-small cell lung cancer

Immunogenic cell death (ICD) converts dying cancer cells into a therapeutic vaccine and stimulates antitumor immune responses. Here we unravel the results of an unbiased screen identifying high-dose (10 µM) crizotinib as an ICD-inducing tyrosine kinase inhibitor that has exceptional antineoplastic a...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Peng, Zhao, Liwei, Pol, Jonathan, Levesque, Sarah, Petrazzuolo, Adriana, Pfirschke, Christina, Engblom, Camilla, Rickelt, Steffen, Yamazaki, Takahiro, Iribarren, Kristina, Senovilla, Laura, Bezu, Lucillia, Vacchelli, Erika, Sica, Valentina, Melis, Andréa, Martin, Tiffany, Xia, Lin, Yang, Heng, Li, Qingqing, Chen, Jinfeng, Durand, Sylvère, Aprahamian, Fanny, Lefevre, Deborah, Broutin, Sophie, Paci, Angelo, Bongers, Amaury, Minard-Colin, Veronique, Tartour, Eric, Zitvogel, Laurence, Apetoh, Lionel, Ma, Yuting, Pittet, Mikael J., Kepp, Oliver, Kroemer, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445096/
https://www.ncbi.nlm.nih.gov/pubmed/30940805
http://dx.doi.org/10.1038/s41467-019-09415-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445096/
https://www.ncbi.nlm.nih.gov/pubmed/30940805
http://dx.doi.org/10.1038/s41467-019-09415-3

Ejemplares similares